WO2005092372A3 - Compositions vaccinales a base de bacillus anthracis modifie et methodes d'utilisation correspondantes - Google Patents

Compositions vaccinales a base de bacillus anthracis modifie et methodes d'utilisation correspondantes Download PDF

Info

Publication number
WO2005092372A3
WO2005092372A3 PCT/US2005/002987 US2005002987W WO2005092372A3 WO 2005092372 A3 WO2005092372 A3 WO 2005092372A3 US 2005002987 W US2005002987 W US 2005002987W WO 2005092372 A3 WO2005092372 A3 WO 2005092372A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacillus anthracis
methods
strains
vaccine compositions
bacteria
Prior art date
Application number
PCT/US2005/002987
Other languages
English (en)
Other versions
WO2005092372A2 (fr
Inventor
Thomas W Dubensky Jr
Daniel A Portnoy
Richard L Calendar
David N Cook
John E Hearst
Original Assignee
Cerus Corp
Teh University Of California
Thomas W Dubensky Jr
Daniel A Portnoy
Richard L Calendar
David N Cook
John E Hearst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/773,618 external-priority patent/US7833775B2/en
Priority claimed from US10/883,599 external-priority patent/US7695725B2/en
Application filed by Cerus Corp, Teh University Of California, Thomas W Dubensky Jr, Daniel A Portnoy, Richard L Calendar, David N Cook, John E Hearst filed Critical Cerus Corp
Priority to US11/173,770 priority Critical patent/US20070031457A1/en
Publication of WO2005092372A2 publication Critical patent/WO2005092372A2/fr
Publication of WO2005092372A3 publication Critical patent/WO2005092372A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une variété de bactéries du Bacillus anthracis modifié, par exemple des souches asporogéniques du Bacillus anthracis. En outre, des souches de Bacillus anthracis sont atténuées dans leur capacité de réparation de l'acide nucléique, comme leur capacité de réparation par excision ou recombinaison d'acide nucléique. L'invention concerne également des souches exprimant un antigène, comme un antigène protecteur, sous le contrôle d'un agent promoteur hétérogène et/ou d'un agent promoteur inductible. L'invention concerne par ailleurs des bactéries du Bacillus anthracis comprenant des mutations dans des gènes de toxines. L'invention concerne en outre des compositions vaccinales comprenant lesdites bactéries, des méthodes de préparation des souches modifiées et des méthodes d'utilisation desdits vaccins.
PCT/US2005/002987 2004-02-06 2005-02-02 Compositions vaccinales a base de bacillus anthracis modifie et methodes d'utilisation correspondantes WO2005092372A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/173,770 US20070031457A1 (en) 2004-02-06 2005-06-30 Modified Bacillus anthracis, vaccine compositions and methods of use thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10/773,618 2004-02-06
US10/773,618 US7833775B2 (en) 2003-02-06 2004-02-06 Modified free-living microbes, vaccine compositions and methods of use thereof
US58488604P 2004-06-30 2004-06-30
US60/584,886 2004-06-30
US10/883,599 US7695725B2 (en) 2003-02-06 2004-06-30 Modified free-living microbes, vaccine compositions and methods of use thereof
US10/883,599 2004-06-30
USPCT/US2004/23881 2004-07-23
PCT/US2004/023881 WO2005009463A2 (fr) 2003-07-24 2004-07-23 Vaccins contre les cellules presentatrices de l'antigene et methodes d'utilisation des vaccins
US59952204P 2004-08-05 2004-08-05
US60/599,522 2004-08-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/773,618 Continuation-In-Part US7833775B2 (en) 2003-02-06 2004-02-06 Modified free-living microbes, vaccine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/173,770 Continuation-In-Part US20070031457A1 (en) 2004-02-06 2005-06-30 Modified Bacillus anthracis, vaccine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2005092372A2 WO2005092372A2 (fr) 2005-10-06
WO2005092372A3 true WO2005092372A3 (fr) 2006-06-08

Family

ID=34972499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002987 WO2005092372A2 (fr) 2004-02-06 2005-02-02 Compositions vaccinales a base de bacillus anthracis modifie et methodes d'utilisation correspondantes

Country Status (1)

Country Link
WO (1) WO2005092372A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
EP1592442A2 (fr) 2003-02-06 2005-11-09 Cerus Corporation Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2008073169A2 (fr) * 2006-08-31 2008-06-19 The Trustees Of The University Of Pennsylvania Procédés, compositions et kits comprenant des vaccins atténués contre l'anthrax et procédés d'administration
IL214246B (en) * 2011-07-21 2018-08-30 Shafferman Avigdor Vaccines produced from htra-defective Bacillus anthraxis
CN108135936A (zh) 2015-06-26 2018-06-08 塞鲁斯公司 冷沉淀物组合物及其制备方法
CA3003097A1 (fr) 2015-10-23 2017-04-27 Cerus Corporation Compositions de plasma et leurs procedes d'utilisation
AU2018227586B2 (en) 2017-03-03 2023-12-21 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
EA202091602A1 (ru) 2017-12-29 2020-10-19 Сирус Корпорейшн Системы и способы для обработки биологических жидкостей
MX2021015653A (es) 2019-06-22 2022-04-11 Cerus Corp Sistemas de tratamiento de fluidos biologicos.
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040046A1 (fr) * 2000-11-16 2002-05-23 Akzo Nobel N.V. Vaccin contre la salmonelle
WO2004084936A2 (fr) * 2003-02-06 2004-10-07 Cerus Corporation Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040046A1 (fr) * 2000-11-16 2002-05-23 Akzo Nobel N.V. Vaccin contre la salmonelle
WO2004084936A2 (fr) * 2003-02-06 2004-10-07 Cerus Corporation Microbes modifies vivant en milieu naturel, compositions de vaccins, et procedes d'utilisation correspondants

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARNARD J P ET AL: "VACCINATION AGAINST ANTHRAX WITH ATTENUATED RECOMBINANT STRAINS OF BACILLUS ANTHRACIS THAT PRODUCE PROTECTIVE ANTIGEN", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 2, February 1999 (1999-02-01), pages 562 - 567, XP002942520, ISSN: 0019-9567 *
BROSSIER F ET AL: "ANTIGEN DELIVERY BY ATTENUATED BACILLUS ANTHRACIS: NEW PROSPECT IN VETERINARY VACCINES", JOURNAL OF APPLIED MICROBIOLOGY, OXFORD, GB, vol. 87, no. 2, August 1999 (1999-08-01), pages 298 - 302, XP000922956, ISSN: 1364-5072 *
COHEN S ET AL: "ATTENUATED NONTOXINOGENIC AND NONENCAPSULATED RECOMBINANT BACILLUS ANTHRACIS SPORE VACCINES PROTECT AGAINST ANTHRAX", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 68, no. 8, August 2000 (2000-08-01), pages 4549 - 4558, XP002942521, ISSN: 0019-9567 *
FERGUSON L R ET AL: "FRAMESHIFT MUTAGENESIS BY NITRACRINE ANALOGUES IN WILD-TYPE UVR-B POL-A AND REC-A STRAINS OF SALMONELLA-TYPHIMURIUM WITH AND WITHOUT PLASMID P-KM-101", MUTATION RESEARCH, AMSTERDAM, NL, vol. 184, no. 1, 1987, pages 13 - 22, XP000926298, ISSN: 0027-5107 *
GUERRY P ET AL: "DEVELOPMENT AND CHARACTERIZATION OF RECA MUTANTS OF CAMPYLOBACTER JEJUNI FOR INCLUSION IN ATTENUATED VACCINES", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 62, no. 2, February 1994 (1994-02-01), pages 426 - 432, XP000992851, ISSN: 0019-9567 *
SANDER P ET AL: "MYCOBACTERIUM BOVIS BCG RECA DELETION MUTANT SHOWS INCREASED SUSCEPTIBILITY OF DNA-DAMAGING AGENTS BUT WILD-TYPE SURVIVAL IN A MOUSE INFECTION MODEL", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 69, no. 5, June 2001 (2001-06-01), pages 3562 - 3568, XP001070859, ISSN: 0019-9567 *
SMITH BRADLEY T ET AL: "Localization of UvrA and effect of DNA damage on the chromosome of Bacillus subtilis", JOURNAL OF BACTERIOLOGY, vol. 184, no. 2, January 2002 (2002-01-01), pages 488 - 493, XP009055970, ISSN: 0021-9193 *

Also Published As

Publication number Publication date
WO2005092372A2 (fr) 2005-10-06

Similar Documents

Publication Publication Date Title
WO2005092372A3 (fr) Compositions vaccinales a base de bacillus anthracis modifie et methodes d'utilisation correspondantes
WO2007024941A3 (fr) Vaccin polyvalent
WO2010019262A3 (fr) Vaccin polyvalent
WO2006017856A3 (fr) Procedes de production de vaccins non antibioresistants
WO2007137075A3 (fr) Utilisation d'espèces batériennes non agrobactériennes pour la transformation de plantes
AU2014203512B2 (en) Recombinant virus-like particles encoded by multi-gene vector
WO2008022298A3 (fr) Polypeptides pcpa immunogènes et utilisations associées
WO2007092792A3 (fr) Vaccin à base de levure destiné à induire une réponse immunitaire
WO2001092539A3 (fr) Procede de production de p-hydroxybenzoate en especes de pseudomonas et d'agrobacterium
WO2009149956A3 (fr) Protéine de fusion et son utilisation
WO2013126387A3 (fr) Composition
WO2008027099A3 (fr) Optimisation de rpa
WO2006055024A3 (fr) Minicellules employees comme vaccins
WO2008108805A3 (fr) Entérobactérie atténuée déficitaire en fnr
WO2008153733A3 (fr) Vecteurs et méthodes pour immunisation génétique
MX2011012234A (es) Plasmido libre de antibiotico.
WO2010120874A3 (fr) Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation
WO2011063350A3 (fr) Procédés et compositions de production de squalène à l'aide de levure
WO2006071989A3 (fr) Methodes de declenchement, d'accentuation et de maintien de reponses immunitaires contre des epitopes restreints du cmh de classe i a des fins prophylactiques ou therapeutiques
WO2008130551A3 (fr) Souche de listeria exempte de résistance aux antibiotiques et procédé pour la construction et l'utilisation de celle-ci
WO2012163817A3 (fr) Composition immunogène
WO2010042749A3 (fr) Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser
WO2008045601A3 (fr) Compositions et méthodes relatives à l'administration d'antigènes à base d'adénovirus
WO2002075507A3 (fr) Preparations de vaccin anti-bacteriennes
WO2007075308A3 (fr) Candidats vaccins contre la maladie de johne

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11173770

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 11173770

Country of ref document: US

122 Ep: pct application non-entry in european phase